Cerevel Therapeutics Holdings, Inc.
CERENext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CERE. That does not mean none is planned.
Get an email about CERE's next catalysts
Track Cerevel Therapeutics Holdings (CERE) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CVL-562 (PF-06412562) | Phase 2 | Early Course Schizophrenia Spectrum Disorder | - | - |
Frequently asked questions
What is in Cerevel Therapeutics Holdings, Inc.'s drug pipeline?β
CatalystAlert tracks 1 drug candidate in Cerevel Therapeutics Holdings, Inc.'s (CERE) pipeline across Phase 2. Its lead program is CVL-562 (PF-06412562) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Cerevel Therapeutics Holdings, Inc.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Cerevel Therapeutics Holdings, Inc. (CERE) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track CERE biotech catalysts?β
Add CERE to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Cerevel Therapeutics Holdings, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
